Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

被引:0
作者
J R Smith
P A Clarke
E de Billy
P Workman
机构
[1] Signal Transduction and Molecular Pharmacology Team,
[2] Cancer Research UK Centre for Cancer Therapeutics,undefined
[3] The Institute of Cancer Research,undefined
[4] Haddow Laboratories,undefined
来源
Oncogene | 2009年 / 28卷
关键词
CDC37; cochaperone; HSP90; client; 17-AAG;
D O I
暂无
中图分类号
学科分类号
摘要
The cochaperone CDC37 promotes the association of HSP90 with the protein kinase subset of client proteins to maintain their stability and signalling functions. HSP90 inhibitors induce depletion of clients, which include several oncogenic kinases. We hypothesized that the targeting of CDC37 using siRNAs would compromise the maturation of these clients and increase the sensitivity of cancer cells to HSP90 inhibitors. Here, we show that silencing of CDC37 in human colon cancer cells diminished the association of kinase clients with HSP90 and reduced levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated AKT. CDC37 silencing promoted the proteasome-mediated degradation of kinase clients, suggesting a degradation pathway independent from HSP90 binding. Decreased cell signalling through kinase clients was also demonstrated by reduced phosphorylation of downstream substrates and colon cancer cell proliferation was subsequently reduced by the inhibition of the G1/S-phase transition. Furthermore, combining CDC37 silencing with the HSP90 inhibitor 17-AAG induced more extensive and sustained depletion of kinase clients and potentiated cell cycle arrest and apoptosis. These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer.
引用
收藏
页码:157 / 169
页数:12
相关论文
共 287 条
  • [1] Banerji U(2008)BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors Mol Cancer Ther 7 737-739
  • [2] Affolter A(2005)Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161
  • [3] Judson I(2002)Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function J Biol Chem 277 39858-39866
  • [4] Marais R(2007)Molecular chaperones and protein kinase quality control Trends Cell Biol 17 87-92
  • [5] Workman P(1998)Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery J Biol Chem 273 35194-35200
  • [6] Banerji U(2000)Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone Oncogene 19 4125-4133
  • [7] O'Donnell A(2001)The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins Nat Cell Biol 3 93-96
  • [8] Scurr M(2005)Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin Cancer Res 65 10686-10691
  • [9] Pacey S(1998)SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins Mol Cell Biol 18 3727-3734
  • [10] Stapleton S(2005)Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells J Biol Chem 280 8875-8883